CLSK three-lens brief
Evidence-based stock research on CLSK. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Outperforming SPY by 42.4pp over 30 days. · Currently unprofitable on a trailing basis — no P/E multiple available.
- Outperforming SPY by 42.4pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Analyst mean target $19.71 — 49% above current (12 analysts).
- Negative free cash flow last quarterly (-$307.70M).
- Debt-to-equity of 129.8 — balance-sheet-heavy.
CLSK closed at $13.25 (-1.63%) as of 2026-05-13. Market cap: $3.40B. Positives: outperforming SPY by 42.4pp over 30 days.; analyst mean target $19.71 — 49% above current (12 analysts).. Concerns: currently unprofitable on a trailing basis — no P/E multiple available.; negative free cash flow last quarterly (-$307.70M).. Last quarter: Revenue $181.18M, net income -$378.71M, free cash flow -$307.70M.
Why three lenses on CLSK, not one.
A single reasoning model has blind spots it doesn’t know about. We examine CLSKacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/CLSK" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath CLSK brief"></iframe>